对407例患者用比特诺尔进行临床验证。结果表明:该药对慢性结肠炎、溃疡性结肠炎、肠易激综合征、消化性溃疡和慢性胃炎的总有效率依次为84.6%、89.5%、88.8%、77.2%和92.0%。且无毒、副反应。并对该药的作用机理进行了初步的探讨。 Forty-seven patients were clinically validated with Butynol. The results showed that the total effective rate of the drug for chronic colitis, ulcerative colitis, irritable bowel syndrome, peptic ulcer and chronic gastritis were 84.6%, 89.5%, 88.8%, 77.2% and 92.0%, respectively. And non-toxic side effects. The mechanism of action of this medicine was also discussed preliminarily.